CN110205270A - A kind of application of lactobacillus paracasei L9 that alleviating cultivated animals constipation - Google Patents
A kind of application of lactobacillus paracasei L9 that alleviating cultivated animals constipation Download PDFInfo
- Publication number
- CN110205270A CN110205270A CN201910483931.4A CN201910483931A CN110205270A CN 110205270 A CN110205270 A CN 110205270A CN 201910483931 A CN201910483931 A CN 201910483931A CN 110205270 A CN110205270 A CN 110205270A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus paracasei
- constipation
- group
- october
- cgmcc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Abstract
The present invention provides the application of lactobacillus paracasei L9 for alleviating cultivated animals constipation a kind of, the lactobacillus paracasei L9 is deposited in China General Microbiological culture presevation administrative center on October 22nd, 2014, and deposit number is CGMCC NO.9800.The lactobacillus paracasei L9, which is one plant, has the bifidobacterium strain compared with strong tolerance energy.The present invention is acted on using the relief of constipation that the bacterial strain is evaluated in zoopery, it is experimentally confirmed that lactobacillus paracasei L9 and its metabolite can promote the secretion of human digestive enzymes and the wriggling of enteron aisle, promote the digestion and absorption of food, improve functions of intestines and stomach, there is good function of relaxing bowel.The lactobacillus paracasei L9 is used to prepare animal feed or pet food, and studies the lactobacillus paracasei and its derivative after confirming the active lactobacillus paracasei and inactivation, all has the effect of improving cultivated animals constipation.
Description
Technical field
The invention belongs to microorganisms technical field, in particular to a kind of lactobacillus paracasei L9 for alleviating cultivated animals constipation
Application.
Background technique
Lactobacillus paracasei is that Abroad in Recent Years studies a kind of more probiotic lactic acid bacteria, and lactobacillus paracasei L9 is one
Strain is widely present in traditional fermented dairy product and human gastrointestinal tract screened from the intestinal excellent probiotic strain of health.
Existing great mass of data shows that lactobacillus paracasei has very wide exploitation and application prospect in field of probiotic bacteria.Currently, research knot
Fruit has confirmed that lactobacillus paracasei has following prebiotic function: (1) antibacterial action.According to the report, lactobacillus paracasei is to food
And some pathogenic bacteria in enteron aisle are inhibited, ferment caused by antibacterial substance to Gram-positive, negative bacterium and
Various pathogens have inhibiting effect；(2) antioxidation.Studies have shown that the bacteria suspension of lactobacillus paracasei, cell-free extraction
Liquid and exocellular polysaccharide all have stronger antioxidant activity；(3) immunoregulation effect.Lactobacillus paracasei can enhance mouse intestines
The immune response in road and system, and it is thin to the delayed allergy of mouse cell, splenic lymphocytes competence for added value and NK
Cytoactive also has remarkable result.
Constipation is one group with defecation frequency reduction, difficult defecation or defecation is felt not to the utmost, excrement is dry and hard, the hard disease being chief complaint
Hou Qun is clinically extremely common symptom.But constipation symptom is not only present in human colony, many animals, especially family
Front yard pet, due to unreasonable diet structure etc., there is also constipation symptoms.
Summary of the invention
Lactobacillus paracasei L9 has stronger acid and bile salt tolerance performance, the potentiality with application and development.Mesh of the invention
Be to provide it is a kind of alleviate cultivated animals constipation lactobacillus paracasei L9 application.
The purpose of the present invention is what is be achieved through the following technical solutions:
A kind of application of lactobacillus paracasei L9 that alleviating cultivated animals constipation, the lactobacillus paracasei L9 was in 2014
It was deposited in China General Microbiological culture presevation administrative center on October 22, deposit number is CGMCC NO.9800.
Further, the lactobacillus paracasei L9 can be applicable to drug, the animal feed that preparation treats or prevents constipation
Or in pet food.
Further, the lactobacillus paracasei L9 is the derivative of viable bacteria, inactivated bacteria or the bacterial strain.
Further, the edible object of the animal feed or pet food is cultivated animals.
Another aspect of the present invention:
A kind of veterinary drug includes lactobacillus paracasei L9 in the veterinary drug, and the lactobacillus paracasei L9 is in October, 2014
It is deposited within 22nd China General Microbiological culture presevation administrative center, deposit number is CGMCC NO.9800, and described secondary dry
The bacterial content of Lactobacillus paracasei L9 is 103-105CFU/g。
A kind of animal feed or pet food include lactobacillus paracasei L9, institute in the animal feed or pet food
It states lactobacillus paracasei L9 and is deposited in China General Microbiological culture presevation administrative center, deposit number on October 22nd, 2014
For CGMCC NO.9800, and the bacterial content of the lactobacillus paracasei L9 is 102-104CFU/g。
The present invention having the beneficial effect that compared with prior art
The relief of constipation effect of the bacterial strain is evaluated in the zoopery of this research and utilization.Balb/c male mice is randomly divided into sky
White group, model group, L9 viable bacteria and the high low dose group of inactivated bacteria.Model group, L9 group establish mice with constipation using compound diphenoxylate
Model, three group model mouse give low, high dose (1 × 10 respectively later4、1×105CFU/mL L9 living bacterial liquid 0.1mL/ (kg)
D), the skimmed milk of blank group and model group stomach-filling 0.1mL/ (kgd) (with constitution meter) mass fraction 10%.It is pushed away using prepared Chinese ink
Defecation situation is evaluated into method.Lactobacillus paracasei L9 be administered 7d after, mice with constipation for the first time defecation time shorten, defecation grain number and
Quality obviously increases, and moisture in feces improves；Continuous 15d stomach-filling lactobacillus paracasei L9, mice with constipation small intestine prepared Chinese ink promote
Rate is also significantly increased.The result shows that lactobacillus paracasei L9 has good function of relaxing bowel.
Specific embodiment
Embodiment 1 --- the verifying of L9 relief of constipation effect
Material:
Balb/c male mice, 6~8 week old, weight 18~22g, SPF grade tie up tonneau China experimental animal purchased from Beijing
Technology Co., Ltd..Lactobacillus paracasei L9 bacterial strain is China Agricultural University's functional dairy products key lab voluntarily separating and preserving bacterium
Strain.
The preparation of solution:
The preparation of prepared Chinese ink: accurately weighing gum arabic 100g, adds water 800mL, boils transparent to solution, weighs activated carbon
(powdery) 50g, which is added in above-mentioned solution, to be boiled 3 times, and after solution is cool plus water constant volume is to 1000mL, and 4 DEG C of preservations in refrigerator are used
Before shake up.
The preparation of compound diphenoxylate suspension (0.05g/100mL and 0.025g/100mL): R-1132, often
Piece 2.5mg containing compound diphenoxylate, take respectively 20 (0.05g/100mL), 10 (0.025g/100mL) with mortar grinding be in
50mL, prepared before use are added water to after powder.
The culture of bacterial strain:
Lactobacillus paracasei L9 bacterial strain, with 37 DEG C of Anaerobic culturel 12h, 4 the 500r/min centrifugations of MRS fluid nutrient medium
15min, bacterial sediment are resuspended in 10% skimmed milk, prepare various concentration bacteria suspension.
Experimental animal grouping and processing:
Experimental strain sets 2 dosage groups, blank group and model group.Blank group and model group intragastric administration on mice mass fraction 10%
Skimmed milk 0.1mL/ (kgd) (with constitution meter)；Lactobacillus paracasei L9 low dosage, high dose group mouse distinguish stomach-filling 1
×106、1×108The viable bacteria of CFU/mL or inactivation bacteria suspension 0.1mL/ (kgd) (with constitution meter).Once a day, experimental period
Between ad lib, record each group mouse changes of body mass.
The experiment of mouse defecation:
After given the test agent 7d, each group mouse is deprived of food but not water 16h.Model group and 2 dosage group intragastric administration on mice are given multiple
Square diphenoxylate (10mg/kg), blank group gives distilled water.2×106、2×108The L9 bacteria suspension and prepared Chinese ink of CFU/mL is isometric
Mixing, after giving compound diphenoxylate 0.5h, blank group and model group intragastric administration on mice prepared Chinese ink 0.1mL/kg (with constitution meter),
Low, high dose group and control group give the prepared Chinese ink 0.1mL/kg (with constitution meter) containing given the test agent, and the equal single cage of animal is raised, just
Often drinking-water feed.Since stomach-filling prepared Chinese ink, records every animal first grain row's melena time, arranges melena grain number, quality in 5h.It collects
Excrement be dried to constant mass at 105 DEG C, by formula (1) calculate dejecta moisture.
Differentiate moisture content (%)=(1-) × 100% (1)
Small intestine push experiment:
After given the test agent 15d, each group mouse is deprived of food but not water 16h.Model and 2 dosage group intragastric administration on mice give compound
Diphenoxylate (5mg/kg), blank control group gives distilled water.After compound diphenoxylate 0.5h, low, high dose group and control
Group gives the prepared Chinese ink 0.1mL/kg (with constitution meter) (sample dose is tested with above-mentioned mouse defecation) containing given the test agent respectively,
He is control group stomach-filling prepared Chinese ink 0.1mL/kg (with constitution meter).Cervical dislocation puts to death mouse immediately after 25min, opens abdominal cavity and separates intestines
Mesentery, clip upper end are placed on pallet from pylorus, lower end to the intestinal tube in ileocecum portion, and small intestine is gently pulled into straight line, measure intestines
Length of tube is " total small intestinal length ", is from pylorus to prepared Chinese ink forward position " prepared Chinese ink propulsion length ".Ink progradation is calculated by formula (2).
Ink progradation (%)=× 100% (2)
Data processing:
Ink progradation need to carry out data conversion, X=Sin-1A, and A is ink progradation in formula, as a result decimally indicate.
When carrying out variance analysis, homogeneity test of variance first is done using variance analysis program, after variance is neat, calculates F value, F value <
Then significant difference respectively is not present between experiment class mean in F0.05；If F value >=F0.05, P≤0.05, show each group mean it
Between there are significant differences；Sum of ranks t inspection is carried out with each experimental group data with a control group.
Mouse changes of body mass:
1 experiment mice changes of body mass (g) of table
This research is carried out under mouse normal physiological condition.As shown in Table 1, during test, the weight of mouse is each
Between dosage group and control group, significant difference (P > 0.05) is not present, lactobacillus paracasei L9 does not have during showing test
Mouse weight is made a significant impact.
Influence of the lactobacillus paracasei L9 to mouse defecation index:
Experiment mice oral stomach-filling lactobacillus paracasei L9 bacterial strain once a day, measurement is to Constipation Model mouse after continuous 7d
The influence that melena granule number, quality and dejecta moisture are arranged in first grain row's melena time, 5h, the results are shown in Table 2.With blank group ratio
The melena time is arranged for the first time compared with, model group mouse, arranges melena granule number, defecation quality and dejecta moisture in 5h and has extremely significant property
Difference (P < 0.01) illustrates that mice with constipation model is set up.
Through stomach-filling 7d, each dosage group mouse of lactobacillus paracasei L9 arranges the melena time for the first time, defecation quality, defecation grain in 5h
Number has all reached extremely significant horizontal (P < 0.01) compared with model group；Low, high dose group mouse defecation moisture content also compares model
Group significantly improves (P < 0.01).And show dosage effect, with the raising of given low, mouse arrange for the first time the melena time,
The indexs such as row's melena granule number, defecation quality and dejecta moisture gradually increase in 5h.
Influence of 2 experimental strain of table to each defecation index of Constipation Model mouse
Note: ##. compared to the blank group, there is extremely significant sex differernce (P < 0.01)；* has extremely significant property compared with model group
Difference (P < 0.01)；* has significant difference (P < 0.05) compared with model group.Following table is same.
The influence that lactobacillus paracasei L9 wriggles to mouse intestinal:
Intestinal motility has 3 kinds of modes, i.e. tension contraction, segmentation movement and wriggling, mainly pushes intestinal contents with peristaltic forces
Movement is major way.It is that a kind of Constipation Model modeling is common that mouse antidiarrheic compound diphenoxylate is given in the oral stomach-filling of this test
Drug, effect mainly directly act on intestinal smooth, by inhibiting intestinal mucosa receptor, eliminate local intestinal mucosa and wriggle
It reflects and slows down intestines peristalsis, make intestinal contents by delay, cause mouse difficult defecation, it is close with constipation clinical symptoms.
Mark observation lactobacillus paracasei thallus to mice with constipation after mouse small intestine wriggling inhibition model is established in stomach-filling, then through prepared Chinese ink
The influence of intestines peristalsis.After experiment mice continuous gavage contains the skimmed milk 15d of lactobacillus paracasei L9 thallus, carries out small intestine and push away
Into experiment, each group mouse small intestine ink progradation is shown in Table 3.
Influence of 3 experimental strain of table to mice with constipation small intestine ink progradation
From table 3 it can be seen that model group ink progradation is significantly lower than blank group (P < 0.01), prepared Chinese ink Promoting Experiment is small
Mouse Constipation Model modeling success.After stomach-filling 15d, each dosage group mouse small intestine ink progradation of lactobacillus paracasei L9 is extremely significant
Higher than model group (P < 0.01).And dosage effect is shown, with the raising of given low, mice with constipation small bowel peristalsis is made
With reinforcement.
Claims (6)
1. a kind of application for the lactobacillus paracasei L9 for alleviating cultivated animals constipation, which is characterized in that the lactobacillus paracasei
L9 is deposited in China General Microbiological culture presevation administrative center, deposit number CGMCC on October 22nd, 2014
NO.9800。
2. application of the lactobacillus paracasei L9 in the drug, animal feed or pet food that preparation treats or prevents constipation,
It is characterized in that, the lactobacillus paracasei L9 was deposited in China General Microbiological culture presevation management on October 22nd, 2014
The heart, deposit number are CGMCC NO.9800.
3. application according to claim 2, which is characterized in that the lactobacillus paracasei L9 is viable bacteria, inactivated bacteria or is somebody's turn to do
The derivative of bacterial strain.
4. application according to claim 2, which is characterized in that the edible object of the animal feed or pet food is feeding
Grow animal.
5. a kind of veterinary drug, which is characterized in that in the veterinary drug include lactobacillus paracasei L9, the lactobacillus paracasei L9 in
It is deposited in China General Microbiological culture presevation administrative center on October 22nd, 2014, deposit number is CGMCC NO.9800, and
And the bacterial content of the lactobacillus paracasei L9 is 103-105CFU/g。
6. a kind of animal feed or pet food, which is characterized in that include secondary cheese cream in the animal feed or pet food
Bacillus L9, the lactobacillus paracasei L9 were deposited in China General Microbiological culture presevation management on October 22nd, 2014
The heart, deposit number is CGMCC NO.9800, and the bacterial content of the lactobacillus paracasei L9 is 102-104CFU/g。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910483931.4A CN110205270B (en) | 2019-06-05 | 2019-06-05 | Application of lactobacillus paracasei L9 for relieving constipation of cultured animals |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910483931.4A CN110205270B (en) | 2019-06-05 | 2019-06-05 | Application of lactobacillus paracasei L9 for relieving constipation of cultured animals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110205270A true CN110205270A (en) | 2019-09-06 |
| CN110205270B CN110205270B (en) | 2023-02-10 |
Family
ID=67790805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910483931.4A Active CN110205270B (en) | 2019-06-05 | 2019-06-05 | Application of lactobacillus paracasei L9 for relieving constipation of cultured animals |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110205270B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110903995A (en) * | 2019-09-30 | 2020-03-24 | 内蒙古伊利实业集团股份有限公司 | Probiotic edible composition and food with digestion promoting effect |
| CN112694989A (en) * | 2020-12-21 | 2021-04-23 | 中国海洋大学 | Lactobacillus paracasei X11 and composition thereof constipation composite preparation and dairy product |
| CN114651984A (en) * | 2022-03-30 | 2022-06-24 | 微康益生菌(苏州)股份有限公司 | Application of lactobacillus casei LC89 and microbial preparation containing same in preparation of product for relieving functional constipation |
| CN115245198A (en) * | 2021-06-25 | 2022-10-28 | 丰宁水星乳品有限责任公司 | Almond powder product capable of relieving functional constipation |
| CN115998777A (en) * | 2022-10-18 | 2023-04-25 | 汤臣倍健股份有限公司 | Use of lactobacillus paracasei 207-27 |
| CN116162570A (en) * | 2023-01-31 | 2023-05-26 | 东北农业大学 | Probiotic composition and preparation method and application thereof |
| CN116549494A (en) * | 2023-07-07 | 2023-08-08 | 四川合泰新光生物科技有限公司 | Beta-1, 3/alpha-1, 3-glucan compound composition with bowel relaxing function and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104523762A (en) * | 2014-12-10 | 2015-04-22 | 中国农业大学 | Application of lactobacillus paracasei having antiallergic effect, functional food composition and preparation method of functional food composition |
| CN104560784A (en) * | 2014-12-10 | 2015-04-29 | 中国农业大学 | Lactobacillus paracasei and application thereof, fermentation product and preparation method thereof |
-
2019
- 2019-06-05 CN CN201910483931.4A patent/CN110205270B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104523762A (en) * | 2014-12-10 | 2015-04-22 | 中国农业大学 | Application of lactobacillus paracasei having antiallergic effect, functional food composition and preparation method of functional food composition |
| CN104560784A (en) * | 2014-12-10 | 2015-04-29 | 中国农业大学 | Lactobacillus paracasei and application thereof, fermentation product and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 宋静颐等: "副干酪乳杆菌L9安全性评价", 《中国奶牛》 * |
| 李桂花等: "含乳益生菌杏仁粉对便秘小鼠的通便作用", 《中国奶牛》 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110903995A (en) * | 2019-09-30 | 2020-03-24 | 内蒙古伊利实业集团股份有限公司 | Probiotic edible composition and food with digestion promoting effect |
| CN110903995B (en) * | 2019-09-30 | 2023-03-24 | 内蒙古伊利实业集团股份有限公司 | Probiotic edible composition and food with digestion promoting effect |
| CN112694989A (en) * | 2020-12-21 | 2021-04-23 | 中国海洋大学 | Lactobacillus paracasei X11 and composition thereof constipation composite preparation and dairy product |
| CN115245198A (en) * | 2021-06-25 | 2022-10-28 | 丰宁水星乳品有限责任公司 | Almond powder product capable of relieving functional constipation |
| CN114651984A (en) * | 2022-03-30 | 2022-06-24 | 微康益生菌(苏州)股份有限公司 | Application of lactobacillus casei LC89 and microbial preparation containing same in preparation of product for relieving functional constipation |
| CN115998777A (en) * | 2022-10-18 | 2023-04-25 | 汤臣倍健股份有限公司 | Use of lactobacillus paracasei 207-27 |
| CN115998777B (en) * | 2022-10-18 | 2023-11-17 | 汤臣倍健股份有限公司 | Use of lactobacillus paracasei 207-27 |
| CN116162570A (en) * | 2023-01-31 | 2023-05-26 | 东北农业大学 | Probiotic composition and preparation method and application thereof |
| CN116162570B (en) * | 2023-01-31 | 2023-10-17 | 东北农业大学 | Probiotic composition and preparation method and application thereof |
| CN116549494A (en) * | 2023-07-07 | 2023-08-08 | 四川合泰新光生物科技有限公司 | Beta-1, 3/alpha-1, 3-glucan compound composition with bowel relaxing function and preparation method and application thereof |
| CN116549494B (en) * | 2023-07-07 | 2023-09-01 | 四川合泰新光生物科技有限公司 | Beta-1, 3/alpha-1, 3-glucan compound composition with bowel relaxing function and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110205270B (en) | 2023-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110205270A (en) | A kind of application of lactobacillus paracasei L9 that alleviating cultivated animals constipation | |
| CN112175864B (en) | Bifidobacterium animalis and breeding method and application thereof | |
| CN107760620B (en) | Lactobacillus plantarum for improving fat-prone constitution and progeny weight and application thereof | |
| CN104758318B (en) | A kind of compound formulation and preparation method thereof reducing diarrhea of weaned piglets rate | |
| CN102549162B (en) | Strains and methods for improving ruminant health and/or performance | |
| CN102711778B (en) | Method for reducing gastro-intestinal inflammation using bifidobacterium animalis bacteria or a fermented dairy product comprising such bacteria | |
| CN110157649A (en) | It is a kind of to have effects that improve the lactobacillus paracasei L9 of people's constipation and its application | |
| CN110317761A (en) | A kind of bifidobacterium lactis and its application | |
| CN114774313B (en) | Use of lactobacillus rhamnosus LRa05 in preparing constipation relieving product or intestinal flora regulating product | |
| CN109182166A (en) | One plant has effects that the Lactobacillus rhamnosus of relief of constipation and its application | |
| CN106860483A (en) | Probiotics complex composition and application containing Bifidobacterium and lactobacillus acidophilus | |
| CN105420150A (en) | Lactobacillus acidophilus and application thereof | |
| CN101449830A (en) | Mid-aged milk powder added with biostime and preparation method thereof | |
| CN109749957A (en) | A kind of preparation and application of the lactobacillus gasseri preparation with aquatic pathogenic bacterium antagonistic properties | |
| CN113249280B (en) | Streptococcus thermophilus STN26, bacterium powder and application in uric acid reducing product | |
| CN101392223A (en) | Breeding method of microbial feed additive strain | |
| CN114540239B (en) | Rabbit-derived enterococcus faecium ZJUIDS-R1 for preventing pet diarrhea and application thereof | |
| CN111011493A (en) | Preparation method of solidified fermented milk rich in animal bifidobacterium and fermented milk prepared by preparation method | |
| CN108938789A (en) | A kind of more bacterium combination formulations of the adjusting intestinal microecology containing xylo-oligosaccharide | |
| CN104431352A (en) | Preparation method of growth-promoting synbiotic bacterium liquid and application | |
| CN115895966B (en) | Bifidobacterium bifidum BL002 for assisting in relieving gout and application thereof | |
| CN104031856B (en) | Lactobacillus casei and application and functional food composition and preparation method thereof | |
| CN110050926A (en) | A kind of preparation method of fermented apple juice that alleviating intestinal bacilli illness | |
| CN112779196B (en) | Composite probiotic preparation for reducing constipation incidence of sows and preparation method and application thereof | |
| CN110897166B (en) | Edible composition containing probiotics and casein phosphopeptide with digestion promoting effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |